Submission guidelines

 

A MyICML account is necessary to log in to the abstract submission system with a unique email address and password.
Notification of evaluation outcome and all correspondence regarding the abstract will be sent to the MyICML email address.

During the submission, an additional email address may be provided to receive a copy of the correspondence.
 

TITLE

May not exceed 170 characters (including spaces).
 

AUTHORS

  • the first author will be responsible for the submission on behalf of the authors;
  • there is no limit to the number of listed authors;
  • the presenting author can be any of the listed authors, provided that eligibility criteria are met. The presenting author’s name will be underlined in the authors’ list.

 

Presenting authors’ eligibility criteria

Representatives of commercial entities (owners or employees of pharmaceutical, diagnostic or biotechnology companies) are eligible to serve as presenting authors for poster presentations.

 

However, they are not allowed to deliver oral presentations.


To ensure that the abstract can be presented if selected for an oral session, at least one author of the abstract must be eligible to present.

In-person participation is required for presenting authors of abstracts selected for oral and poster presentation.

If the assigned presenting author cannot attend the meeting and present the abstract, a replacement must be designated from the list of authors and communicated  to abstract@icml.ch.

 

 

POTENTIAL SOURCES OF CONFLICT OF INTEREST

Disclosure of all potential sources of conflict of interest, directly relevant or directly related to the work described in the abstract, is requested for each author.

 

Potential sources of conflict of interest

 

Any financial interest or relationship that might be perceived as influencing an author's objectivity is considered a potential source of conflict of interest.
Potential sources of conflict of interest include but are not limited to:

  • employment or leadership position in a company;
  • consultant or advisory role;
  • stock ownership;
  • honoraria;
  • travel grants.


 

 

TEXT

May not exceed 3000 characters (including spaces).

 

All abstracts (except for Ongoing Trials abstracts) should include the following four sections:

  • Introduction;
  • Methods;
  • Results;
  • Conclusions.

Drugs should be mentioned with the generic name in lower case. Commercial names must not be used.

 

Abbreviations are permitted but terms must be spelt out at their first mention in the text and followed by the abbreviation in parentheses, i.e. International Conference on Malignant Lymphoma (ICML).
 

IMAGE, GRAPH OR TABLE
One image, graph or table can be submitted, as a separate file.
The system accepts only one file, up to 10 MB.
JPEG, GIF or PNG files can be uploaded, with the following resolution criteria:

  • Graphs and tables: 800 dpi preferred; 600 dpi minimum;
  • Images: 300 dpi minimum.

Images, graphs and tables without readable text may be removed from the Abstract Book without further recourse to the authors.

 

RESEARCH FUNDING DECLARATION
Disclose of commercial, public, or private foundation grants.

 

CATEGORIES
(minimum 1 – maximum 3), to be selected from the "Abstract Categories list", available here:

 

Abstract Categories list

 

ENCORE ABSTRACTS
Only abstracts submitted and published and/or presented at the following international meetings, which are organised in the same period as 18-ICML (March - June 2025), can be submitted to the 18-ICML:

  • EBMT (European Bone Marrow Transplant), 30 March - 2 April 2025;
  • AACR (American Association for Cancer Research), 25 - 30 April 2025;
  • ASCO (American Society of Clinical Oncology), 30 May – 3 June 2025;
  • EHA (European Hematology Association), 12 – 15 June 2025.

In addition, encore abstracts will be accepted if they have been submitted and published and/or presented at regional or national meetings with up to 1000 attendees.
The Encore abstract checkbox must be ticked at the time of submission.
 

UPDATED ANALYSIS
Abstracts published and/or presented at other international meetings than EBMT, AACR, ASCO, EHA 2025 will be considered only if significant novel information is added to previous publications.
At the time of submission, the previous publication and the novel information can be indicated in the “Updated Analysis” field.
 

ONGOING TRIAL ABSTRACTS
Abstracts describing trials in progress can be submitted, provided that patient enrollment has already started at the time of submission.
Ongoing trials abstracts are required to include Introduction and Methods sections only (no results or preliminary data must be included).
Only the scientific and clinical rationale of the trial will be evaluated.
The “Ongoing Trial” checkbox must be ticked at the time of submission.
 

PREFERRED PRESENTATION FORMAT
At the time of submission, the preferred presentation format can be selected:

  • oral presentation (general sessions and “Focus on…” sessions);
  • poster presentation;
  • no preference.

The Organising Committee reserves the right to ultimately decide the presentation format, taking into account the evaluation results and the structure of the Scientific Programme.

 

OPT-OUT FROM ABSTRACT BOOK (in case of selection for “Publication only”)
All abstracts that have been selected for oral or poster presentation will be included in the 18-ICML Abstract Book.

Abstracts selected for “publication only” will be included in the 18-ICML Abstract Book, unless explicitly indicated at the time of submission by ticking the “Opt-out from Abstract Book” checkbox.

 

APPLICATION FOR A TRAVEL GRANT
Subject to funding availability, a limited number of travel grants will be awarded to young investigators (under 35 years old), designated as the presenting authors of the abstracts accepted for oral or poster presentation.
The selection will be made based on the abstract evaluation results.

Eligible presenting authors can apply for the travel grant at the time of abstract submission by selecting the “Travel grant” check box.
 

ADDITIONAL CONTACT EMAIL
in addition to the Submitter (who is the primary contact), the additional contact will receive all notifications concerning the evaluation outcome and future correspondence regarding the abstract.
 

ACCEPTANCE OF SUBMISSION REQUIREMENTS AND AUTHORS’ RESPONSIBILITIES
(see the relevant page).
 

Corrigenda
Once the abstract has been submitted, corrigenda (corrections, rewording or amendments to the text and change of order of the list of authors) cannot be made.

If an error in a submitted abstract is discovered after the deadline, the presenting author may draw attention to the correction during the presentation (in the case of acceptance of the abstract for oral or poster presentation).
The ICML Secretariat is not authorised to make changes to a submission.

 

Withdrawal policy
No abstract withdrawal request will be accepted after the submission deadline.